Five Under 5: Top Oncology Videos for the Week of 12/21

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

Here’s what you may have missed:

Updated Safety Findings With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–Positive TNBC: Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, as well as an associate professor of medicine at Harvard Medical School, summarized updated safety findings from the phase 3 ASCENT-04 trial (NCT05382286) evaluating sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) in patients with PD-L1–positive triple-negative breast cancer (TNBC), building on data from the study previously reported earlier in 2025.

Findings presented at the 2025 San Antonio Breast Cancer Symposium showed that the incidence of grade 3 or higher treatment-emergent adverse effects (TEAEs) was higher in the experimental arm (n = 221) at 71% (exposure-adjusted incidence rate [EAIR], 2.19; 95% CI, 1.86-2.56) vs 70% (EAIR, 2.13; 95% CI, 1.81-2.49) in the control arm (n = 220). However, TEAEs led to dose reductions of sacituzumab govitecan in 35% of patients (EAIR, 0.62; 95% CI, 0.49-0.78) vs 44% of patients who required a chemotherapy dose reduction (EAIR, 0.94; 95% CI, 0.76-1.15).

Pediatric-Inspired Regimens for Adolescents and Young Adults With ALL: Marlise Rachael Luskin, MD, MSCE

Marlise Rachael Luskin, MD, MSCE, associate program director of the Dana-Farber/Mass General Brigham Hematology/Oncology Fellowship Program and education director for the Adult Leukemia Program, reviewed the rationale and practical considerations for using pediatric-inspired regimens in adolescents and young adult (AYA) patients with acute lymphoblastic leukemia (ALL), highlighting how these approaches have reshaped outcomes in this population.

Frontline Chemotherapy Selection in Pancreatic Cancer: Zev A. Wainberg, MD

Zev A. Wainberg, MD, a professor of medicine and co-director of the UCLA GI Oncology Program at the University of California, Los Angeles, discussed prominent frontline chemotherapy regimens for patients with metastatic pancreatic cancer, such as, NALIRIFOX (irinotecan liposome [Onivyde], oxaliplatin, 5-fluorouracil [5-FU], and leucovorin), FOLFIRINOX (leucovorin, 5-FU, irinotecan, and oxaliplatin), and gemcitabine plus nab-paclitaxel (Abraxane), as well as data from the phase 3 NAPOLI-3 study (NCT04083235), which compared NALIRIFOX vs gemcitabine plus nab-paclitaxel.

The Timing of Next-Generation Sequencing in NSCLC: Adam Fox, MD

Adam Fox, MD, an assistant professor in the Department of Medicine in the College of Medicine at the Medical University of South Carolina, discussed the process and timing of ordering next-generation sequencing (NGS) in patients with non–small cell lung cancer (NSCLC).

Fox explained that although NGS has largely become the standard of care in the United States for patients with NSCLC, especially those with metastatic disease, it remains unclear if every patient with early-stage disease needs to undergo testing. Fox noted that NGS takes time and costs money, and he highlighted that not all of the testing results may be required before a surgical approach, with or without systemic therapy, is selected. There are likely centers that are not performing NGS for patients with early-stage disease and favor more targeted testing approaches for these patients, he added.

The Role of FES-PET/CT in the Diagnosis of Lobular Breast Cancer: Jason A. Mouabbi, MD

Jason A. Mouabbi, MD, an assistant professor in the Department of Breast Medical Oncology, Division of Cancer Medicine, as well as an assistant professor in the Department of General Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discussed the role of 18F-fluoroestradiol (FES)–PET/CT imaging in the diagnosis of lobular breast cancer.

FES-PET/CT is not intended to be used to monitor a patient’s response to treatment, Mouabbi began. Instead, the imaging modality should be used to answer clinical questions at specific time points, he explained. For example, in patients with early-stage disease, FES-PET/CT can be used to see is the cancer has metastasized to distant location, he noted.